Core Viewpoint - The report discusses the development and market potential of HDAC/PI3Kα dual-target inhibitors, highlighting their mechanisms, current market status, and future prospects in the pharmaceutical industry. Group 1: Mechanism and Importance - PI3K is a crucial enzyme in the PI3K-Akt-mTOR signaling pathway, which is significant in cancer, immune response, and thrombosis control [3][4] - HDACs play a vital role in gene expression regulation and chromatin structure modification, with abnormal acetylation levels linked to cancer and immune diseases [4][5] - The combination of HDAC and PI3K inhibitors shows synergistic anti-tumor effects, enhancing therapeutic efficacy against various cancers [5][6] Group 2: Market Status - As of June 30, 2025, only BEBT-908 has been approved for market, while several PI3K inhibitors have been approved in China, including Duvelisib and Lymphocil [7][8] - The approved HDAC inhibitors in China include Vorinostat and Entinostat, with specific indications for various cancers [8] Group 3: Research and Development - Ongoing clinical trials for PI3K and HDAC inhibitors include drugs like Aibestatin and Puyisitan, targeting relapsed or refractory diffuse large B-cell lymphoma [9][10] - The report outlines the current R&D status of these inhibitors, indicating a growing pipeline in the oncology sector [10][11] Group 4: Industry Analysis - The report provides a comprehensive analysis of the economic, policy, social, and technological environments affecting the HDAC/PI3Kα dual-target inhibitor industry in China [10][11] - It also discusses the competitive landscape, market structure, and future trends in the industry, emphasizing the importance of multi-target pharmacology [5][6][10]

Market Overview - US stock market continues to rise with increasing expectations of interest rate cuts, leading to a slight opening increase in Hong Kong stocks, with the Hang Seng Index up 0.17% at 25,804.01 points [1] - Major technology stocks mostly rose, with Alibaba down 0.33%, Tencent down 0.16%, JD.com up 0.61%, Xiaomi up 0.3%, NetEase up 0.32%, Meituan up 0.94%, and Kuaishou up 0.07% [1] - The innovative drug concept opened high, with Gilead Sciences up over 3% and BeiGene up 3.1% [1] - Real estate stocks were active, with China Oceanwide Holdings up over 1% [1] - The non-ferrous metals sector performed actively, with Chalco International up 7.17% and Luoyang Molybdenum up 3.43% [1] - Airline stocks opened lower, with China Eastern Airlines down over 1% [1] - Robotics concept stocks opened high, with Sanhua Intelligent Control up 5.67% and Yujian up 4.06% [1] Company News - InnoCare Pharma (02577.HK) has reached a strategic cooperation agreement with ON Semiconductor to accelerate the development of the GaN industry ecosystem [2] - The collaboration aims to integrate InnoCare's advanced GaN manufacturing capabilities with ON Semiconductor's expertise in system packaging and integration, potentially generating hundreds of millions in GaN sales over the next few years [2] - Agile Group (03383.HK) reported a total pre-sale amount of approximately 8.08 billion, a year-on-year decrease of 45.2% [3] - Jingrui Holdings (01862.HK) reported a cumulative contract sales amount of approximately 876 million, a year-on-year decrease of 54.1% [4] - China Aluminum International (02068.HK) announced that its subsidiary won a bid for a new 394,000 tons/year electrolytic aluminum project in Shanxi, with a total contract price of 3.03 billion [4] - Stone Pharmaceutical Group (01093.HK) received clinical trial approval for a selective 5-HT2A receptor agonist in the US [5] - Fosun Pharma (02196.HK) received clinical trial approval for its subsidiary's FXS887 tablets [6] - Zai Lab (02617) had its Tislelizumab tablets included in the priority review list by the National Medical Products Administration [7] - Deking Pharma (06996) received approval in Hong Kong for its Hivio® to treat two new indications: multiple myeloma and diffuse large B-cell lymphoma [7] - Kaisa Group (01813) has postponed its liquidation hearing to December 8 [8] Industry Insights - According to CCB International, domestic demand policies are being promoted, and the market is focusing on the "New Year" expectations [9] - After the consolidation in November, the Hong Kong stock market is expected to welcome a layout window for the year-end rally in December [9] - The focus is shifting from external environments to internal policies, with attention on the Central Economic Work Conference scheduled for mid-December [9] - Tianfeng Securities reported that most northern provinces have begun implementing staggered production during the heating season, with over 85% of clinker lines in a shutdown state [9] - The overall staggered production efforts have strengthened, with Hunan planning a month-long shutdown in December due to environmental pressures [9] - The bottom profitability support for cement is strong in the short term, with head enterprises starting to address overproduction capacity indicators [9]

Market Dynamics - LME metal futures closed higher, with LME copper rising by $342 to a record high of $11,488 per ton, and LME tin increasing by $1,740 to $40,780 per ton, marking the largest increase in copper delivery applications since 2013 with a surge of 50,575 tons to 56,875 tons [1] - The U.S. stock market saw a significant rise in robotics stocks, with Nauticus Robotics soaring over 135% and iRobot nearly 80%, following reports of the White House's plans to accelerate the development of the robotics industry [1] - The ADP report indicated a surprising decline in U.S. private sector employment by 32,000 jobs in November, contrasting with the previously revised increase of 47,000 jobs in October, raising concerns about the labor market [2] Industry Developments - Credo, a leader in the active copper cable (AEC) sector, reported Q2 FY2026 revenue of $268 million, a 272% year-over-year increase, highlighting growth driven by AI in the copper cable and AEC industry [7] - The upcoming 2025 Cultivated Diamond Industry Conference in Zhengzhou is expected to benefit from the rising demand for diamonds in semiconductor cooling applications, with the global cultivated diamond market projected to grow to 36.8 billion yuan by 2025 [8] - OpenAI is addressing increased error rates in its ChatGPT service for enterprise clients and has finalized the acquisition of Neptune, a startup focused on AI model training monitoring tools [11] Company Announcements - Arrow Yuan Technology has established a large-scale liquid rocket production and testing base in Hangzhou with a total investment of 5.2 billion yuan, aiming for an annual production capacity of 25 units of the Yuan Voyager-1 rocket [5] - Ideal Automotive launched its first AI smart glasses, Livis, priced from 1,999 yuan, with a government subsidy reducing the price to 1,699 yuan for orders placed before December 31 [6] - Macro Construction announced that its bipedal humanoid robot, Matrix Super Intelligence, will officially launch its next-generation product next year [13]

Core Viewpoint - The approval of SYH2056 by the FDA for clinical trials in the U.S. marks a significant milestone for the company, indicating potential growth in the treatment of depression [1] Company Summary - The company, Shijiazhuang Yiling Pharmaceutical, has developed a new chemical drug, SYH2056, which is a selective 5-HT2A receptor agonist aimed at improving the condition of patients with depressive disorders [1] - SYH2056 has also received approval from the National Medical Products Administration in China to conduct clinical trials starting November 2025 [1] Product Details - SYH2056 is designed to provide rapid onset of action with lasting effects and does not carry the risk of inducing hallucinations [1] - The clinical indication for SYH2056 is specifically for the treatment of depression [1]

Core Viewpoint - The A+H pharmaceutical sector continues to adjust, with significant fluctuations in the market, particularly in innovative drugs, indicating potential investment opportunities as bottom-fishing capital emerges [1][5][16]. Group 1: Market Performance - The largest medical ETF in the market (512170) and the only drug ETF (562050) fell by 0.58% and 0.19% respectively, while the Hong Kong innovative drug ETF (520880) dropped by 1.43% [1][5]. - A-share medical leaders mostly declined, with WuXi AppTec down 2.01%, and both Aier Eye Hospital and Tigermed down over 1%, while some stocks like Yingke Medical and New Industry saw gains [1][12]. - The medical ETF (512170) hit a four-month low during intraday trading, closing below all moving averages, but saw over 1.14 billion yuan in net subscriptions as investors sought to buy the dip [1][16]. Group 2: Sector Analysis - The pharmaceutical sector in A-shares showed relative resilience, with the drug ETF (562050) outperforming the market, primarily due to gains from traditional Chinese medicine leaders like Pian Zai Huang and Yunnan Baiyao [3][12]. - The innovative drug sector displayed divergence, with Yifan Pharmaceutical surging by 6.11%, while major stocks like BeiGene fell by 1.59% [3][12]. - The drug ETF (562050) has about 25% weight in traditional Chinese medicine, which helps mitigate the high volatility of innovative drugs, thus reducing the overall volatility and drawdown of the pharmaceutical index [3][12]. Group 3: Future Outlook - The innovative drug sector is expected to be a major upward trend heading into 2026, as the industry continues to experience strong demand and unmet needs, with increased R&D investments from pharmaceutical companies [7][16]. - Analysts suggest that the current adjustment phase may present a favorable long-term investment opportunity in pharmaceutical assets, particularly as the sector shows signs of recovery [16]. - The Hong Kong innovative drug ETF (520880) is recommended for balanced internal allocation strategies, with a focus on improving fundamentals in the innovative drug supply chain [7][16].

Core Viewpoint - The company has received approval from the U.S. Food and Drug Administration (FDA) for its Class 1 chemical drug, a selective 5-HT2A receptor agonist, to conduct clinical trials in the United States [1] Group 1 - The selective 5-HT2A receptor agonist is designed to improve the condition of patients with depressive disorders [1] - The drug shows rapid onset of action with a single dose and has a long-lasting effect without causing hallucinogenic risks [1] - The product has also been approved by the National Medical Products Administration (NMPA) of China to conduct clinical trials in China starting from November 2025 [1]

Core Viewpoint - The company, Stone Pharmaceutical Group, has received approval from the U.S. Food and Drug Administration (FDA) for its novel chemical entity, SYH2056, a selective 5-HT2A receptor agonist, to conduct clinical trials in the U.S. This product has also been approved by the National Medical Products Administration (NMPA) in China for clinical trials starting in November 2025 [1]. Group 1 - The product SYH2056 is designed to improve the condition of patients with depressive disorders by activating the 5-HT2A receptor, showing rapid onset of action with lasting effects and no risk of hallucinations [1]. - The clinical indication for SYH2056 is the treatment of depression, with preclinical studies demonstrating its effectiveness in promoting dendritic and dendritic spine generation in central nervous neurons, indicating potential for neuroplasticity [1]. - In various animal models of depression, SYH2056 exhibited excellent antidepressant activity while significantly reducing the potential hallucinogenic risks associated with the target, alongside favorable pharmacokinetic (PK) properties and safety, positioning it as a potential best-in-class antidepressant [1]. Group 2 - The clinical demand for SYH2056 is substantial due to the limitations of traditional antidepressants and the lack of new mechanism-based treatments for depressive disorders, highlighting its high clinical development value [1]. - The company has submitted multiple patent applications for SYH2056 both domestically and internationally, indicating a strong commitment to protecting its intellectual property [1].

Core Viewpoint - The announcement highlights that the pharmaceutical company has received approval from the U.S. Food and Drug Administration (FDA) for its novel Class 1 chemical drug, SYH2056, a selective 5-HT2A receptor agonist, to conduct clinical trials in the U.S. and has also received approval from the National Medical Products Administration (NMPA) in China for clinical trials starting in November 2025 [1] Group 1 - The product is designed to activate the 5-HT2A receptor to improve the condition of patients with depressive disorders, showing rapid onset of action and prolonged efficacy without the risk of hallucinations [1] - The clinical indication for the approved trials is the treatment of depression, with preclinical studies demonstrating effective promotion of dendritic and dendritic spine generation in central nervous neurons, indicating a potential for neuroplasticity [1] - In various animal models of depression, the product has shown excellent antidepressant activity while significantly reducing the potential hallucinogenic risks associated with the target, along with favorable pharmacokinetic (PK) properties and safety, positioning it as a best-in-class antidepressant [1] Group 2 - The clinical demand for this product is substantial due to the numerous clinical treatment inadequacies of traditional antidepressants and the lack of new mechanism drug therapies for depressive disorders, indicating high clinical development value [1]

Core Viewpoint - The company has received approval from the U.S. Food and Drug Administration (FDA) for its novel chemical drug SYH2056, a selective 5-HT2A receptor agonist, to conduct clinical trials in the U.S. [1] - The product has also been approved by the National Medical Products Administration (NMPA) of China for clinical trials starting in November 2025 [1] Group 1 - SYH2056 is designed to improve the condition of patients with depressive disorders by activating the 5-HT2A receptor, providing rapid onset of action with lasting effects and no hallucinogenic risks [1] - The clinical indication for this product is specifically for the treatment of depression [1] - Preclinical studies indicate that SYH2056 effectively promotes the generation of dendrites and dendritic spines in central nervous neurons, demonstrating neuroplasticity effects [1] Group 2 - In various animal models of depression, SYH2056 has shown excellent antidepressant activity while significantly reducing the potential hallucinogenic risks associated with the target [1] - The product exhibits favorable pharmacokinetic (PK) characteristics and safety, positioning it as a potential best-in-class antidepressant [1] - The company has submitted multiple patent applications for this product both domestically and internationally [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 （股份代號：1093） （於香港註冊成立之有限公司） 自願公告 選擇性5 -HT2A受體激動劑（SYH2056片） 在美國獲臨床試驗批准 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）董 事 會（「 董 事 會 」）欣 然 宣 布， 本集 團開 發的 化藥 1 類新 藥選 擇性 5 -羥 色胺 2A 受體（「5 -HT2A 受體」）激 動劑（ SYH2056 片 ）（「該產品」）已獲得美國食品藥品監督管理局批准，可在美國開展臨床試驗。該產品亦已 於2025年11月獲得中華人民共和國國家藥品監督管理局批准在中國開展臨床試驗。 該產品為一種選擇性5 -HT2A受體激動劑，通過激活該受體改善抑鬱障礙患者的疾病狀態， 單次給藥即可快速起效，藥效持久，且 ...